Theodoros Karantanos, MD, PhD

Primary Academic Title

Assistant Professor of Oncology

Background

Research Interests

Molecular biology and targeted therapies in high-risk MDS and AML

Lab Website

Karantanos Lab 

Research Summary

My research focuses on the dissection of the role of inflammatory signaling and development of novel targeted therapies in high-risk and particularly TP53 mutated MDS/AML. My work incorporates gene editing by CRISPR-Cas9, signal transduction analysis, progenitor assays, drug and CRISPR-Cas9 knockout screens, development of antibody-based therapies and MDS/AML xenograft models.

Our lab studies the molecular biology of inflamamtory signaling regulation in high-risk MDS/AML and investigates novel therapies that can effectively target these pathways using in vitro and in vivo models.

Google Scholar

https://scholar.google.com/citations?hl=en&user=boJ6-cwAAAAJ

PubMed

https://pubmed.ncbi.nlm.nih.gov/?term=Karantanos+T&sort=date

Selected Publications

• Karantanos T, Chaturvedi S, Braunstein EM, Spivak JL, Resar L, Karanika S, Williams D, Rogers O, Gocke C, Moliterno AR. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020 Jun 23;4(12):2567-2576

• Karantanos T, Gondek LP, Varadhan R. Moliterno AR, Dezern AE, Jones RJ, Jain T. Gender-related differences in the outcomes and genomic landscape of patients with MDS/MPN. Br J Haematol. 2021 Jun;193(6):1142-1150

• Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, Dalton WB, Christodoulou I, Paun BC, Varadhan R, Esteb C, Rajkhowa T, Bonifant C, Gondek LP, Levis MJ, Yegnasubramanian S, Ghiaur G, Jones RJ. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. Haematologica. 2023 April

• Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, Helmenstine E, Rajkhowa T, Paun BC, Bonifant C, Dalton WB, Gondek LP, Moliterno AR, Levis MJ, Ghiaur G, Jones RJ. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Sci Adv. 2022 Feb 18;8(7):eabl8952

• Karantanos T, Tsai HL, Gondek LP, DeZern AE, Ghiaur G, Dalton WB, Gojo I, Prince GT, Webster J, Ambinder A, Smith BD, Levis MJ, Varadhan R, Jones RJ, Jain T. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leuk Lymphoma. 2022 Aug;63(8):1942-1948

Patents

C17672 Targeting CCRL2 in MDS and sAML

Honors

• HMBMT Pilot Grant, 4/2024
• Leukemia Research Foundation Young Investigator Award, 6/2023
• K08 Clinical Scientist Research Career Development Award, NIH/NHLBI, 4/24/23
• Passano Award, Passano Foundation, 3/1/23
• Clinician Scientist Award, Johns Hopkins University, 1/1/23
• MacMillan Pathway to Independence Program, Sidney Kimmel Cancer Center, 7/1/22
• Research Training Award for Fellows, American Society of Hematology, 7/1/21
• Physician Scientist Johns Hopkins Training Program Grant, 1/1/21
• T32 Training Program in Hematology, Johns Hopkins University, 7/1/19
• Prostate Cancer Foundation (PCF) Young Investigator Award, 5/1/13
• Hellenic Society of Medical Oncology Young Investigator Award, 7/1/12

Memberships

• American Society of Hematology
• American Society of Clinical Oncology
• American Association for Cancer Research
• American Society of Transplantation and Cellular Therapy